Safety and Efficacy of AGN 203818 for Pain Associated With Painful Bladder Syndrome/Interstitial Cystitis

This study has been terminated.

Sponsored by:	Allergan
Information provided by:	Allergan
ClinicalTrials.gov Identifier:	NCT00380783

Purpose

This study will explore the safety and effectiveness of different doses of AGN 203818 in treating the pain associated with painful bladder syndrome/interstitial cystitis

Condition	Intervention	Phase
Cystitis, Interstitial	Drug: AGN 203818	Phase II

MedlinePlus related topics: Interstitial Cystitis

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study

Further study details as provided by Allergan:

Primary Outcome Measures:

Reduction in daily pain scores

Estimated Enrollment:	200
Study Start Date:	September 2006

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Female
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Diagnosis of painful bladder syndrome/interstitial cystitis
Moderate or severe bladder pain

Exclusion Criteria:

Any other uncontrolled disease
Pregnant or nursing females

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00380783

Locations

United States, Oklahoma

Oklahoma City, Oklahoma, United States

Sponsors and Collaborators

Allergan

More Information

Study ID Numbers:	203818-005
Study First Received:	September 22, 2006
Last Updated:	June 26, 2007
ClinicalTrials.gov Identifier:	NCT00380783
Health Authority:	United States: Food and Drug Administration

Study placed in the following topic categories:

Cystitis, Interstitial
Cystocele
Urologic Diseases

Urinary Bladder Diseases
Cystitis
Pain

ClinicalTrials.gov processed this record on January 16, 2009